Fernandez-Bussy Sebastian, Chandra Nikitha C, Koratala Anoop, Yu Lee-Mateus Alejandra, Barrios-Ruiz Alanna, Garza-Salas Ana, Koirala Tapendra, Funes-Ferrada Rodrigo, Balasubramanian Prasanth, Patel Neal M, Chadha Ryan, Hazelett Britney N, Robertson Kelly S, Reisenauer Janani, Abia-Trujillo David
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL, USA.
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL, USA.
J Thorac Dis. 2024 Aug 31;16(8):5422-5434. doi: 10.21037/jtd-24-456. Epub 2024 Aug 28.
Robotic-assisted bronchoscopy (RAB) has emerged as an advanced technology for lung cancer diagnosis. This review explores the three approved robotic bronchoscopy systems: Ion™ Endoluminal (Intuitive Surgical, Sunnyvale, CA, USA), Monarch™ (Johnson & Johnson, Redwood City, CA, USA), and Galaxy System™ (Noah Medical, San Carlos, CA, USA), and their different operational systems. This narrative review aims to summarize their findings and outcomes for sampling peripheral pulmonary lesions (PPL) suspected of lung cancer.
A search in PubMed and Google Scholar databases was conducted for articles and abstracts published between January 2018 to May 2024 using the terms "robotic bronchoscopy" or "robotic-assisted bronchoscopy" for biopsy of PPL.
Lung cancer is the leading cause of cancer-related mortality. The introduction of RAB aims to improve the feasibility and safety of sampling PPL. Current literature describes high diagnostic yields with low risk of complications, allowing concurrent hilar and mediastinal staging within the same procedure. RAB can potentially improve early diagnosis and treatment of pulmonary malignancies and survival rate in long term, while progressing towards therapeutic applications in the near future.
As RAB evolves, its potential as a "one-stop shop" for diagnosis, staging, and treatment can positively impact lung cancer detection, focusing on improved patient-centered outcomes and reducing multiple diagnostic and therapeutic procedures.
机器人辅助支气管镜检查（RAB）已成为肺癌诊断的一项先进技术。本综述探讨了三种已获批的机器人支气管镜系统：Ion™ 腔内系统（直观外科手术公司，美国加利福尼亚州桑尼维尔）、Monarch™（强生公司，美国加利福尼亚州红木城）和Galaxy System™（诺亚医疗公司，美国加利福尼亚州圣卡洛斯），以及它们不同的操作系统。本叙述性综述旨在总结它们对疑似肺癌的周围肺病变（PPL）进行采样的研究结果和结局。
在PubMed和谷歌学术数据库中进行检索，使用“机器人支气管镜检查”或“机器人辅助支气管镜检查”等术语搜索2018年1月至2024年5月期间发表的关于PPL活检的文章和摘要。
肺癌是癌症相关死亡的主要原因。RAB的引入旨在提高PPL采样的可行性和安全性。当前文献描述了其诊断率高且并发症风险低，能够在同一手术中同时进行肺门和纵隔分期。RAB有可能改善肺恶性肿瘤的早期诊断和治疗以及长期生存率，同时在不久的将来朝着治疗应用方向发展。
随着RAB的不断发展，其作为诊断、分期和治疗“一站式服务”的潜力可对肺癌检测产生积极影响，重点在于改善以患者为中心的结局并减少多次诊断和治疗程序。
